Search results for "BEVACIZUMAB"

showing 10 items of 162 documents

Radiotherapy prolongs the survival of advanced non-smallcell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned ci…

2017

// Pierpaolo Pastina 1 , Valerio Nardone 1 , Cirino Botta 2 , Stefania Croci 1 , Paolo Tini 1 , Giuseppe Battaglia 1 , Veronica Ricci 3 , Maria Grazia Cusi 4 , Claudia Gandolfo 4 , Gabriella Misso 5 , Silvia Zappavigna 5 , Michele Caraglia 5,6 , Antonio Giordano 6,7 , Donatella Aldinucci 8 , Pierfrancesco Tassone 2,6 , Pierosandro Tagliaferri 2 , Luigi Pirtoli 1 and Pierpaolo Correale 1,9 1 Radiotherapy Unit, Department of Medicine, Surgery, and Neuroscience, Siena University Hospital, Siena, Italy 2 Medical Oncology Unit, AUO “Mater Domini”, “Magna Graecia” University, Catanzaro, Italy 3 Radiology Unit,Department of Medicine, Surgery, and Neuroscience, Siena University Hospital, Siena, Ita…

0301 basic medicineOncologymedicine.medical_specialtyRetrospective analysiBevacizumabmedicine.medical_treatmentRetrospective analysisNSCLC03 medical and health sciences0302 clinical medicineInternal medicineMedicineLung cancerEtoposideCisplatinbusiness.industryMetronomic chemotherapyAbscopal effectmedicine.diseaseMetronomic ChemotherapyImmune-modulationSurgeryRadiation therapyRadiation therapyRegimen030104 developmental biologyOncology030220 oncology & carcinogenesisNSCLC; immune-modulation; metronomic chemotherapy; radiation therapy; retrospective analysisbusinessmedicine.drugResearch Paper
researchProduct

Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation

2016

// Nicoletta Staropoli 1, * , Domenico Ciliberto 1, * , Silvia Chiellino 1 , Francesca Caglioti 1 , Teresa Del Giudice 1 , Simona Gualtieri 1 , Angela Salvino 1 , Alessandra Strangio 1 , Cirino Botta 1 , Sandro Pignata 2 , Pierfrancesco Tassone 1, * , Pierosandro Tagliaferri 1, * 1 Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy 2 Department of Gynecologic and Urologic Oncology, Fondazione Pascale, National Cancer Institute of Naples, Naples, Italy * These authors have contributed equally to this work Correspondence to: Pierosandro Tagliaferri, email: tagliaferri@unicz.it Keywords: ovarian cancer, targeted therapy, systemic chemotherapy, systemat…

0301 basic medicineOncologymedicine.medical_specialtyTime FactorsBevacizumabmedicine.medical_treatmentAngiogenesis InhibitorsDisease-Free SurvivalTargeted therapyTargeted therapy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsOvarian cancerInternal medicineBiomarkers TumorOdds RatiomedicineHumansMeta-analysiMolecular Targeted TherapyPrecision MedicineSystemic chemotherapyOvarian Neoplasmsbusiness.industryPatient SelectionHazard ratioCancermedicine.diseaseCarboplatinmeta-analysisClinical trialTreatment Outcome030104 developmental biologyOncologychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisMeta-analysisDisease ProgressionSystematic reviewFemalePersonalized medicinebusinessResearch PaperSignal Transductionmedicine.drug
researchProduct

Two-Week Aflibercept or Erlotinib Administration Does Not Induce Changes in Intestinal Morphology in Male Sprague–Dawley Rats But Aflibercept Affects…

2019

Gastrointestinal toxicity is a frequently observed adverse event during cancer treatment with traditional chemotherapeutics. Currently, traditional chemotherapeutics are often combined with targeted biologic agents. These biologics, however, possess a distinct toxicity profile, and they may also exacerbate the adverse effects of traditional chemotherapeutics. In this study, we aimed to characterize the gastrointestinal and metabolic changes after a 2-week treatment period with aflibercept, an antiangiogenic VEGFR decoy, and with erlotinib, a tyrosine-kinase inhibitor. Male rats were treated either with aflibercept or erlotinib for 2 weeks. During the 2-week treatment period, the animals in …

0301 basic medicineOriginal articleCancer ResearchBevacizumabANTITUMOR-ACTIVITYmedicine.medical_treatmentBEVACIZUMAB3122 CancersAdipose tissuePharmacologylcsh:RC254-282TOXICITY03 medical and health sciences0302 clinical medicinemedicineOXIDATIVE STRESSCOMBINATIONAdverse effectAfliberceptChemotherapyIntestinal permeabilitybusiness.industryCHEMOTHERAPYmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthMETASTATIC COLORECTAL-CANCER1ST-LINE TREATMENT030104 developmental biologyOncology030220 oncology & carcinogenesisCELLSACIDToxicityErlotinibbusinessmedicine.drug
researchProduct

Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phas…

2018

IF 5.503 (2017); International audience; In preclinical models, IL-1β inhibition could enhance the efficacy of fluorouracil (5-FU). In this phase 2 study, we assessed the activity and safety of 5-FU plus bevacizumab and anakinra (an IL-1β and α inhibitor) in patients with metastatic colorectal (mCRC) refractory to chemotherapy and anti-angiogenic therapy. Eligible patients had unresectable mCRC; were refractory or intolerant to fluoropyrimidine, irinotecan, oxaliplatin, anti-VEGF therapy, and anti-EGFR therapy (for tumors with wild-type KRAS). Patients were treated with a simplified acid folinic plus 5-FU regimen and bevacizumab (5 mg/kg) both administered by intravenous infusion for 30 min…

0301 basic medicinelcsh:Immunologic diseases. Allergymedicine.medical_specialtyBevacizumabImmunologyPhases of clinical research[SDV.CAN]Life Sciences [q-bio]/CancerNeutropeniaGastroenterologyclicial trial optimizationlcsh:RC254-28203 medical and health sciences0302 clinical medicineInternal medicinemedicinetherapeutic trialsImmunology and Allergyil1colorectalnew targetsAnakinrabusiness.industryclinical trialmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthOxaliplatinIrinotecanRegimen030104 developmental biologyOncologyFluorouracil030220 oncology & carcinogenesischemoimmunotherapymdscbusinesslcsh:RC581-607medicine.drugOncoimmunology
researchProduct

Indications and practice of diverting ileostomy after colorectal resection and anastomosis in ovarian cancer cytoreduction.

2020

Objective. To determine the factors related with diverting ileostomy performance after colorectal resection and anastomosis, in advanced ovarian cancer cytoreductive surgery. Methods. We have previously demonstrated the risk factors associated with anastomotic leak after colorectal anastomosis: Advanced age at surgery, low serum albumin level, additional bowel resections, manual anastomosis and distance of the anastomosis from the anal verge. However, use of diverting ileostomy is strongly variable and depends on individual surgeon preferences and training. Eight hospitals participated in this retrospective study. Data of 695 patients operated for ovarian cancer with primary colorectal anas…

0301 basic medicinemedicine.medical_specialtyBevacizumabAnastomotic LeakGynecologic oncologyAnastomosisStomaCohort Studies03 medical and health sciences0302 clinical medicineDiverting ileostomyOvarian cancerAnastomotic leakMedicineHumansPractice Patterns Physicians'AgedNeoplasm StagingRetrospective StudiesOvarian Neoplasmsbusiness.industryIleostomyAnastomosis SurgicalObstetrics and GynecologyRetrospective cohort studyPerioperativeCytoreduction Surgical Proceduresmedicine.diseaseNeoadjuvant TherapySurgeryBevacizumab030104 developmental biologyRisk factorsOncology030220 oncology & carcinogenesisCohortFemaleRisk factorbusinessOvarian cancerColorectal Neoplasmsmedicine.drugGynecologic oncology
researchProduct

INTRAVITREAL BEVACIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY

2017

PURPOSE To evaluate the effects of intravitreal bevacizumab (IVB) on retinal neovascularization in patients with proliferative diabetic retinopathy (PDR). METHODS Retrospective multicenter interventional case series. A chart review was performed of 81 consecutive patients (97 eyes) with retinal neovascularization due to PDR, who received at least 1 IVB injection. RESULTS The mean age of the patients was 55.6 ± 11.6 years. The mean number of IVB injections was 4 ± 2.5 injections (range, 1-8 injections) per eye. The mean interval between IVB applications was 3 ± 7 months. The mean duration of follow-up was 29.6 ± 2 months (range, 24-30 months). Best-corrected visual acuity and optical coheren…

0301 basic medicinemedicine.medical_specialtyVisual acuitygenetic structuresBevacizumabmedicine.medical_treatmentVitrectomy03 medical and health sciences0302 clinical medicineOphthalmologymedicineAdverse effectRetinabusiness.industryRetrospective cohort studyGeneral MedicineDiabetic retinopathymedicine.diseaseeye diseasesOphthalmology030104 developmental biologymedicine.anatomical_structureVitreous hemorrhage030221 ophthalmology & optometrysense organsmedicine.symptombusinessmedicine.drugRetina
researchProduct

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice

2019

Alessio Cortellini,1,2 Katia Cannita,1 Alessandro Parisi,1,2 Paola Lanfiuti Baldi,1 Olga Venditti,1 Carla D’Orazio,1,2 Antonella Dal Mas,3 Giuseppe Calvisi,3 Aldo V Giordano,4 Vincenzo Vicentini,5 Roberto Vicentini,5 Lara Felicioni,6 Antonio Marchetti,7 Fiamma Buttitta,6 Antonio Russo,8 Corrado Ficorella1,2 1Medical Oncology, St Salvatore Hospital, University of L’Aquila, L’Aquila, Italy; 2Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy; 3Department of Pathology, St Salvatore Hospital L’Aquila, L’Aquila, Italy; 4Diagnostic and Interventional Radiology, St Salvatore Hos…

5-fluorouracil infusion; Bevacizumab; Clinical practice; Intensive chemotherapy regimen; Metastatic colorectal cancerintensive chemotherapy regimenmetastatic colorectal cancer intensive chemotherapy regimen bevacizumab clinical practice 5-fluorouracil infusionmetastatic colorectal cancer5-fluorouracil infusionbevacizumabOncoTargets and TherapyOriginal Researchclinical practiceOncoTargets and therapy
researchProduct

The role of adiponectin and leptin in the treatment of ovarian cancer patients

2019

Introduction: Ovarian cancer is most frequently detected in the advanced stage. Although its pathogenesis is not fully elucidated, it is assumed that body susceptibility and hormonal disorders are responsible. The role of some cytokines as predictors in the treatment process is still investigated. The aim of the study was to determine the relationship of adiponectin and leptin with the disease severity and response to chemotherapy. Material and methods: Forty-three ovarian cancer patients were treated by systemic treatment. Patients received 5–7 cycles of chemotherapy — paclitaxel/carboplatin with or without bevacizumab. Using standard ELISA kits before and after chemotherapy, adiponectin a…

AdultLeptinmedicine.medical_specialtyPaclitaxelBevacizumabEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAdipokine030209 endocrinology & metabolismGastroenterologyCarboplatin03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyBlood serumInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedAged 80 and overOvarian NeoplasmsChemotherapyAdiponectinbusiness.industryLeptinMiddle Agedmedicine.diseaseCarboplatinBevacizumabTreatment OutcomechemistryFemaleAdiponectinOvarian cancerbusinessBiomarkershormones hormone substitutes and hormone antagonistsmedicine.drugEndokrynologia Polska
researchProduct

Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306)

2016

We explored the association of early tumor shrinkage (ETS) and non-ETS with efficacy of first-line and consecutive second-line treatment in patients with KRAS wild-type metastatic colorectal cancer treated in FIRE-3. Assessment of tumor shrinkage was based on the sum of longest diameters of target lesions, evaluated after 6 weeks of treatment. Shrinkage was classified as ETS (shrinkage by ≥ 20%), mETS (shrinkage by 0 to20%), mPD (minor progression0 to20%) and PD (progression ≥20%). Overall survival (OS) was 33.2 (95% CI 28.0-38.4) months in ETS patients, while non-ETS was associated with less favorable outcome (mETS 24.0 (95% CI 21.2-26.9) months, mPD 19.0 (95% CI 13.0-25.0) months, PD 12.8…

AdultMale0301 basic medicineCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancerLeucovorinCetuximabKaplan-Meier Estimatemedicine.disease_causeGastroenterologyDisease-Free SurvivalProto-Oncogene Proteins p21(ras)03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedShrinkageCetuximabbusiness.industryRemission InductionTumor shrinkageMiddle Agedmedicine.diseaseBevacizumabTreatment Outcome030104 developmental biologyOncologyFluorouracil030220 oncology & carcinogenesisFOLFIRICamptothecinFemaleFluorouracilKRASColorectal Neoplasmsbusinessmedicine.drugInternational Journal of Cancer
researchProduct

Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudores…

2017

Abstract Background Response Assessment in Neuro-Oncology Criteria (RANO), are used to asses response to first-line treatment of glioblastoma (GBM). Differentiation between response and pseudoresponse under treatment with Bevacizumab (BVZ) remains challenging. This study evaluates ADC changes in patients with radiographic pseudoresponse under treatment with (BVZ). Methods Patients (n = 40) with recurrent GBM under-treatment with BVZ underwent MRI before, two and four months after treatment with BVZ. In patients with radiological pseudoresponse (n = 11), ADC analyses were performed. Areas with decreasing T1 contrast enhancement (CE) and FLAIR signal decrease were manually selected and compar…

AdultMaleBevacizumabRadiographyPseudoresponseFluid-attenuated inversion recovery030218 nuclear medicine & medical imaging03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineImage Interpretation Computer-AssistedmedicineHumansEffective diffusion coefficientRadiology Nuclear Medicine and imagingIn patientAgedRadiological and Ultrasound TechnologyBrain Neoplasmsbusiness.industryMiddle Agedmedicine.diseaseHyperintensityBevacizumabbody regionsDiffusion Magnetic Resonance ImagingTreatment OutcomeFemaleNeurology (clinical)Neoplasm Recurrence LocalGlioblastomabusinessNuclear medicine030217 neurology & neurosurgerymedicine.drugGlioblastomaJournal of Neuroradiology
researchProduct